Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.

Literature DB >> 27806236

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.

Christoph Wanner¹, Silvio E Inzucchi², Bernard Zinman³.

Abstract

Entities: Disease

Mesh：

Substances：

Year: 2016 PMID： 27806236 DOI： 10.1056/NEJMc1611290

Source DB: PubMed Journal: N Engl J Med ISSN： 0028-4793 Impact factor: 91.245

Keyword Cloud
Cited

× No keyword cloud information.

55 in total

Review 1. SGLT2 inhibition and heart failure-current concepts.

Authors: Joaquim Silva Custodio; Andre Rodrigues Duraes; Marconi Abreu; Natalia Albuquerque Rocha; Leonardo Roever
Journal: Heart Fail Rev Date: 2018-05 Impact factor: 4.214

2. Renal tubule insulin receptor modestly promotes elevated blood pressure and markedly stimulates glucose reabsorption.

Authors: Jonathan M Nizar; Blythe D Shepard; Vianna T Vo; Vivek Bhalla
Journal: JCI Insight Date: 2018-08-23

3. Empagliflozin, SGLT₂ inhibitor, attenuates renal fibrosis in rats exposed to unilateral ureteric obstruction: potential role of klotho expression.

Authors: Noha A T Abbas; Amal El Salem; Mohammed M Awad
Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 2018-08-08 Impact factor: 3.000

Review 4. Empagliflozin: A Review in Type 2 Diabetes.

Authors: James E Frampton
Journal: Drugs Date: 2018-07 Impact factor: 9.546

Review 5. Are SGLT2 Inhibitors Ready for Prime Time for CKD?

Authors: Roberto Pecoits-Filho; Vlado Perkovic
Journal: Clin J Am Soc Nephrol Date: 2017-09-11 Impact factor: 8.237

Review 6. Sodium glucose cotransporter (SGLT)-2 inhibitors: Do we need them for glucose-lowering, for cardiorenal protection or both?

Authors: Rosalie A Scholtes; Michaël J B van Baar; Yuliya Lytvyn; Petter Bjornstad; Max Nieuwdorp; David Z I Cherney; Daniël H van Raalte
Journal: Diabetes Obes Metab Date: 2019-04 Impact factor: 6.577

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.

Review 1. SGLT2 inhibition and heart failure-current concepts.

2. Renal tubule insulin receptor modestly promotes elevated blood pressure and markedly stimulates glucose reabsorption.

3. Empagliflozin, SGLT₂ inhibitor, attenuates renal fibrosis in rats exposed to unilateral ureteric obstruction: potential role of klotho expression.

Review 4. Empagliflozin: A Review in Type 2 Diabetes.

Review 5. Are SGLT2 Inhibitors Ready for Prime Time for CKD?

Review 6. Sodium glucose cotransporter (SGLT)-2 inhibitors: Do we need them for glucose-lowering, for cardiorenal protection or both?

Review 7. Renal Effects of Sodium-Glucose Co-Transporter Inhibitors.

Review 8. [Chronic kidney disease : What is currently available for treatment?]

Review 9. Regulating Autophagy as a Therapeutic Target for Diabetic Nephropathy.

Review 10. Bridging the Gap for Patients with Diabetes and Cardiovascular Disease Through Cardiometabolic Collaboration.

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.

Review 1. SGLT2 inhibition and heart failure-current concepts.

2. Renal tubule insulin receptor modestly promotes elevated blood pressure and markedly stimulates glucose reabsorption.

3. Empagliflozin, SGLT2 inhibitor, attenuates renal fibrosis in rats exposed to unilateral ureteric obstruction: potential role of klotho expression.

Review 4. Empagliflozin: A Review in Type 2 Diabetes.

Review 5. Are SGLT2 Inhibitors Ready for Prime Time for CKD?

Review 6. Sodium glucose cotransporter (SGLT)-2 inhibitors: Do we need them for glucose-lowering, for cardiorenal protection or both?

Review 7. Renal Effects of Sodium-Glucose Co-Transporter Inhibitors.

Review 8. [Chronic kidney disease : What is currently available for treatment?]

Review 9. Regulating Autophagy as a Therapeutic Target for Diabetic Nephropathy.

Review 10. Bridging the Gap for Patients with Diabetes and Cardiovascular Disease Through Cardiometabolic Collaboration.

3. Empagliflozin, SGLT₂ inhibitor, attenuates renal fibrosis in rats exposed to unilateral ureteric obstruction: potential role of klotho expression.